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Abstract
Background: Clinicians, hospital managers, policy makers, and researchers are concerned about high costs, increased
demand, and variation in priorities in the intensive care unit (ICU). The objectives of this modelling study are to
describe the extra costs and expected health gains associated with admission to the ICU versus the general ward for
30,712 patients and the variation in cost-effectiveness estimates among subgroups and individuals, and to perform a
distribution-weighted economic evaluation incorporating extra weighting to patients with high severity of disease.
Methods: We used a decision-analytic model that estimates the incremental cost per quality-adjusted life year (QALY)
gained (ICER) from ICU admission compared with general ward care using Norwegian registry data from 2008 to 2010.
We assigned increasing weights to health gains for those with higher severity of disease, defined as less expected
lifetime health if not admitted. The study has inherent uncertainty of findings because a randomized clinical trial
comparing patients admitted or rejected to the ICU has never been performed. Uncertainty is explored in probabilistic
sensitivity analysis.
Results: The mean cost-effectiveness of ICU admission versus ward care was €11,600/QALY, with 1.6 QALYs gained and
an incremental cost of €18,700 per patient. The probability (p) of cost-effectiveness was 95% at a threshold of €22,000/
QALY. The mean ICER for medical admissions was €10,700/QALY (p = 97%), €12,300/QALY (p = 93%) for admissions
after acute surgery, and €14,700/QALY (p = 84%) after planned surgery. For individualized ICERs, there was a 50%
probability that ICU admission was cost-effective for 85% of the patients at a threshold of €64,000/QALY, leaving 15%
of the admissions not cost-effective. In the distributional evaluation, 8% of all patients had distribution-weighted ICERs
(higher weights to gains for more severe conditions) above €64,000/QALY. High-severity admissions gained the most,
and were more cost-effective.
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Conclusions: On average, ICU admission versus general ward care was cost-effective at a threshold of €22,000/QALY
(p = 95%). According to the individualized cost-effectiveness information, one in six ICU admissions was not cost-
effective at a threshold of €64,000/QALY. Almost half of these admissions that were not cost-effective can be regarded
as acceptable when weighted by severity of disease in terms of expected lifetime health. Overall, existing ICU services
represent reasonable resource use, but considerable uncertainty becomes evident when disaggregating into
individualized results.
Keywords: Intensive care, Cost-effectiveness, Severity of disease, Quality-adjusted life years, Resource allocation, Health
priorities
Background
Clinicians, hospital managers, policy makers, and re-
searchers are concerned about high costs, increased de-
mand, and variation in priorities in intensive care [1–7].
Population-level studies find that, on average, admission
of critically ill patients to intensive care units (ICUs) ver-
sus non-intensive care is cost-effective [8–10]. It does
not necessarily follow that every individual ICU admis-
sion represents efficient resource use; the critically ill are
a diverse group of patients [11]. However, certain
characteristics among the patients may justify higher re-
source use. Society may accept higher costs per unit of
health gain among severe cases compared to less severe
cases [12–14]. A better understanding of individual vari-
ation in terms of severity of disease, cost, and effects of
ICUs is therefore needed.
Analysis of the extra costs and health gains associated
with ICU admission versus some next-best treatment
option for the critically ill could inform ICU priorities
[15, 16]. Robust estimates of the real health benefits and
extra costs of ICU admission are unavailable because the
alternative to ICU admission—the appropriate com-
parator—is hard to quantify since randomised controlled
trials (RCTs) cannot be performed due to ethical reasons
[9, 15, 17]. Previous cost-effectiveness analyses (CEAs)
of intensive care have used average cost-effectiveness
ratios or assumed that patients incur no costs and die if
not admitted to the ICU [8, 18–20]. Two cost-
effectiveness analyses from Europe compared ICU admis-
sion to non-intensive care [9, 10]. Acknowledging meth-
odological constraints, the authors concluded that ICU
admission represents good value for money and can com-
pare with other essential health care services. Few cost-
effectiveness studies of ICU admission take into account
important individual variability in terms of the patients’
death risks, age, treatment needs and resource use, and
potential survival benefit of admission [11, 21–24].
Rationing intensive care is inevitable and should follow
explicit criteria such as cost-effectiveness [25, 26]. Cost-
effectiveness must be balanced against other concerns that
may conflict with or are not always captured by the use of
CEAs—e.g. “rule of rescue”—the imperative to save pa-
tients from imminent death, respect for autonomy, or
disease-related severity [14, 27, 28]. Expected lifetime
health can be used to compare severity across diseases
and individuals and is discussed as an explicit criterion for
priority setting in Norway and endorsed by the World
Health Organization under the name of priority to the
worse off [13, 29]. A high risk of imminent death, pro-
found pain, functional deterioration or reduced health-
related quality of life, early rather than late onset of illness
in life, and long duration of illness or disability will each,
or together, contribute to a high degree of severity of dis-
ease. The ethical rationale is that patients with higher se-
verity of disease deserve extra priority; improving their
situation may reduce inequalities in expected lifetime
health between patient groups with different conditions
[30, 31]. White et al. proposed that a similar lifecycle
argument could guide priorities in life support during a
public emergency [32]. An explicit concern for severity of
disease is rarely integrated into CEAs [33].
A substantial increase in ICU capacity may be neces-
sary in the coming decades because of increased demand
due to an ageing population and changing disease pat-
terns [7]. Since CEA is increasingly used to judge the
value of different types of health care (predominantly
new interventions), we sought to evaluate the opportun-
ity cost of ICU admission compared with some next-
best alternative. It is impossible to remove confounding
from such comparisons since we do not have good data
from clinical trials. This modelling exercise necessarily
requires a number of general assumptions about the dif-
ferences in short- and long-term mortality, health-
related quality of life, and resource use between those
admitted or hypothetically not admitted to the ICU.
The aims of this paper are to describe the extra costs
and expected health gains associated with admission to
the ICU versus the general ward for 30,712 patients, and
the variation in cost-effectiveness estimates among sub-
groups and individuals, and to perform a distribution-
weighted economic evaluation incorporating extra
weighting to patients with high severity of disease.
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Methods
Conventional cost-effectiveness analysis
We developed a micro-simulation model to estimate the
expected incremental cost in Euro (€) per quality-
adjusted life year (QALY) gained from ICU admission
for each individual ICU patient compared to hypo-
thetical ICU rejection (resembling general ward care) of
the same patient. The second best treatment option in
our setting would be a regular hospital ward unequipped
to provide highly specialized organ support. Interme-
diate care units are uncommon. The Norwegian Inten-
sive Care Registry (NIR) is a good source of data for a
model aiming to describe the variability of the cost-
effectiveness of ICU admissions because it contains
individual-level data on age, the length of the ICU stay,
and death risk. Information about the study population,
setting, and key model assumptions and parameters are
included in Table 1. We updated a previously published
model predicting the life expectancy of NIR patients
from 2008 to 2010 (n = 40,916) [34]. Patients with miss-
ing data, Simplified Acute Physiology Score (SAPS) II
<1, ICU re-admission during the same hospital stay, or
transfers to other hospitals were excluded. A total of
30,712 ICU patients were included in this study. Details
of the excluded patients were reported previously [34].
Table 2 includes baseline characteristics of the study
population. We used input from secondary sources when
needed. The literature search is shown in Additional file 1.
For each treatment alternative in the micro-simulation,
a Markov process was run separately for 30,712 individ-
uals to account for the variability of individual model in-
put values represented by their unique profiles of
predicted short-term risk of death based on SAPS II, age,
and length of ICU stay obtained from NIR [35]. In prob-
abilistic sensitivity analysis, we ran the cohort of all indi-
viduals 1000 times and sampled from the range of
possible parameters for each mean value. The uncertainty
around each variable is based on reported cost data or
previous studies (modified SAPS II model, health-related
quality of life (HRQoL) weights, long-term mortality, total
length of hospital stay, cost of ICU and general ward bed
day, mean annual health care cost 5 years after initial hos-
pital discharge) [36].
Health gain from ICU admission
We assumed the benefits of ICU admission versus ward
care as displayed in Fig. 1 where the absolute short-term
survival benefit (Fig. 1 and Additional file 2) [21, 37]: a)
increases with SAPS II, and indirectly with age since
SAPS II is age-weighted; b) peaks around mid- to high-
range SAPS II; c) diminishes in each end of the SAPS II
range, i.e. if too well or too sick to benefit, respectively;
and d) can differ between patients too well and too sick
to benefit, i.e. at each end of the SAPS II range.
The assumptions were based on a systematic search
and rapid review of studies estimating the mortality
impact of ICU admission compared with refusal
(Additional files 1 and 2). The lower limit of the benefit
assumption was based on the original SAPS II model
published in 1993 which implies that admitting critically
ill to general wards today would have about the same
hospital mortality as admitting these patients to ICUs in
the late 1980s (Fig. 1 and Additional file 2).
Subsequent survival after hospital discharge was esti-
mated using the same life tables for both treatment op-
tions, corrected for excess mortality in ICU survivors,
and adjusted by age-specific HRQoL weights from the
general population. The HRQoL was down-weighted by
20% over the first 5 years after the hospital stay because
we assumed that the HRQoL of ICU survivors persists
at a lower level than the general population (Table 1 and
Additional file 2) [19, 38–42].
Resource use
We used a top-down costing method. The estimated cost
of an ICU admission took into account both the cost of
the initial hospital stay and resource use among survivors
up to 5 years after discharge. Similar estimates were ob-
tained for patients if treated in the general ward. The extra
cost of ICU admission versus ward care for an individual
patient was the difference between the estimated total
ICU and ward costs, given the patient’s characteristics.
The cost per day in the ICU is highest in the first 24 h
and then falls substantially [4, 43]. Normalised to the
average cost of an ICU bed-day, we modelled ICU daily
costs such that ICU days 1 and 2 were 3- and 1.5-times
costlier, respectively, than ICU day 3 onwards. The ward
stay cost post-ICU was estimated by multiplying the
length of stay with the average cost of a general ward
bed-day. We used distributions of the average cost of an
ICU bed-day, €3980 (range €2390 to €5570), and the
average cost of a general ward bed-day, €640 (range
€320 to €950), based on data emerging from hospitals
piloting a cost-per-patient specification issued by The
Norwegian Directorate of Health (Table 1, see also
Additional file 2) [44].
If the patient was not admitted to the ICU but treated
in the general ward, we modelled the daily cost over the
course of an individual’s estimated length of hospital
stay. Assuming that these patients would demand extra
resources in the ward, the first days were weighted dif-
ferentially as described above, but normalised to the
average cost of a general ward bed-day, €640 (range
€320 to €950) (see Additional file 2).
NIR provides an individual’s observed length of the ICU
stay (LOS ICU). For a patient admitted to the ICU, we cal-
culated the expected LOS ICU as the weighted sum of
sampled LOS of individuals of the same age group (age ±5
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years) and the same type of admission from three categor-
ies in NIR: those who died in the ICU (66% of the non--
survivors), died in the ward (34% of the non-survivors), or
survived hospital (weighted by the patient’s probability of
dying or surviving the hospital stay given by calibrated
SAPS II; Tables 1 and 2). The expected number of ward
days following ICU discharge (LOS ward) was estimated
based on available references from Norway and a Euro-
pean multi-centre study of ICU triage [37, 45, 46]. For
ICU decedents, we set LOS ward to 0 days, and for those
who died in the ward after ICU discharge we sampled
LOS ward from a distribution of possible values (mean 2.5
days). For hospital survivors, LOS ward was sampled from
a different distribution with a mean of 10 days. Then the
weighted sum was calculated (Table 1).
The expected total hospital LOS for a patient being
admitted to the general ward was based on what their
total hospital LOS would have been if admitted to the
ICU. If the patient would have died in the ICU, the total
hospital LOS was reduced by 10% on average. If the pa-
tient would have survived the hospital stay, the total
hospital LOS was increased by 10% on average. Then
the weighted sum was calculated based on the patient’s
probability of dying or surviving the hospital stay in the
case of general ward treatment (given by modified SAPS
II; Tables 1 and 2). These assumptions allow for a
Fig. 1 Short-term survival benefit of admission to the ICU versus the general ward: assumptions. SAPS II versus risk of death if admitted to the
intensive care unit (ICU) or general ward (base case). Multiple grey lines represent the range of modified SAPS II models used in the analysis of
uncertainty. For a given SAPS II, the vertical distance between the two lines represents the absolute short-term survival benefit of ICU admission
compared to general ward care. For example, a sepsis patient with a predicted hospital mortality of 40% with treatment in the ICU would be
attributed an absolute mortality reduction of 42% from admission (indicated by arrow, corresponding relative risk ratio = 0.49). The mountain-like
grey shape at the bottom shows the distribution of patients according to SAPS II
Table 2 Baseline characteristics of the study population




n 30,712 17,122 9722 3868
Age (years)
Mean (SD) 63.2 (18.2) 63.7 (18) 61.4 (19.3) 65.2 (15.4)
Q1 52.4 53.4 48 57.2
Median 66 66.5 64.7 67.5
Q3 77.3 77.7 77 76.5
SAPS II
Mean (SD) 36.8 (18.2) 38.6 (18.8) 36.9 (17.2) 29 (16)
Q1 24 25 24.2 18
Median 34 36 35 25
Q3 47 49 47 37
Survival status (proportion)
Died ICU 0.13 0.15 0.12 0.05
Died ward 0.07 0.07 0.06 0.05
Survived hospital 0.81 0.78 0.82 0.9
LOS ICU (days)
Mean (SD) 4.3 (6.8) 4 (6.4) 5 (7.5) 3.8 (6.6)
Q1 1.1 1 1.3 1.1
Median 2 1.9 2.3 1.9
Q3 4.3 4 5.2 3.4
ICU intensive care unit, LOS length of stay, Q quartile, SAPS Simplified Acute
Physiology Score, SD standard deviation
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patient treated in the general ward to have a longer or
shorter hospital stay than if admitted to the ICU.
Survivors of critical illness demand substantial health
care resources in the years following hospital discharge
[47]. Data on long-term health care resource use among
survivors from the general ICU population is lacking in
Norway. In a recent study from Scotland, Lone et al.
found that over a 5-year follow-up period more than
80% of an ICU cohort had at least one hospital admis-
sion, with a mean of 4.8 admissions [48]. They reported
mean annual hospital costs per years 1 to 5, which we
included in our model with broad ranges around the
mean values. We assumed that long-term hospital costs
were equal between survivors of the two treatment op-
tions, and calculated the weighted sum for each patient.
Norwegian guidelines for health economic evaluations
recommend that we use cost per QALY analysis and that
a 4% annual discount rate is applied to both health bene-
fits and costs. A health care provider perspective is used
here [49, 50]. Costs were converted from Norwegian
kroner (NOK) to Euros (€) using OECD purchasing
power parities [51].
Distribution-weighted economic evaluation
We explored a method to incorporate a concern for se-
verity of disease into CEAs by assigning higher weights
to health gains for patients with less expected lifetime
health without the intervention in question [14]. Life-
time QALYs have been suggested as a measure that
can be used to compare severity across diseases and
individuals [13, 52, 62] . For a patient referred to the
ICU, the lifetime QALYs were calculated by the sum of
a) past years lived with a quality of life as the general
population at specific ages and b) the future QALYs given
the increased risk of death and loss of quality of life due to
acute illness or trauma if rejected to the ICU. In this
model, severity of disease depends on short- and long-
term risk of death, age, and HRQoL in the past and future.
Additional file 2 provides details of the weighting
function.
Scenario analyses
In one scenario analysis, we applied an almost constant
ICU or ward daily cost (days 1, 2, and 3 were 1.2-, 1.1-,
and 1.05-times costlier, respectively, than day 4 on-
wards), acknowledging that the variation in the cost
from one day to another may not be as substantial as re-
ported elsewhere due to high staffing (nurse:patient ra-
tio), short mean and median ICU stays, and a low
number of ICU beds to hospital beds and population
size (Table 2) [5]. In another scenario analysis, we
accounted for lifetime health care costs beyond 5 years
among hospital survivors, as recommended by US gen-
eral and ICU guidelines for CEAs, to improve the
generalizability of our findings [27, 53]. Out of NOK 277
billion public spending on health care in 2016, about
50% (€2070 per capita) goes to curative care mainly in
hospitals, and about 30% (€1190 per capita) to long-
term care in facilities or at home [54]. We added the
average annual health care cost (mean €2070, range ±
€1190) from year 6 after the initial hospital stay (scaled
beta distribution: €880 + (€3260 – €880) × beta(alpha =
2,beta = 2).
All calculations and analyses were performed using R
programming [55]. A cost-effectiveness threshold range
between €22,000 and €64,000/QALY was used as a refer-
ence. This is supported by a recent White Paper
endorsed by Parliament, even if there is no officially
approved cost-effectiveness threshold in Norway.
Threshold levels vary by severity of disease, where severe
diseases have higher thresholds and less severe diseases
have lower thresholds. The minimum threshold
should correspond to the opportunity cost in the
health services, which has been estimated to be about
NOK 275,000 (€22,000) [56]. Currently, the national
Decision Forum approves reimbursement of new




Mean results from the standard cost-effectiveness
analysis based on aggregated individual results, i.e.
the sum of extra costs divided by the sum of gains
for all patients and by type of admission, are shown
in Table 3. The cost-effectiveness of ICU admission
versus ward care was €11,600/QALY, with 1.6 QALYs
gained from ICU admission and an incremental cost
of €18,700 per patient. Medical admissions (€10,700/
QALY) had a more favourable incremental cost-
effectiveness ratio (ICER) than admissions after acute
surgery (€12,300/QALY) and after planned surgery
(€14,700/QALY).
Figure 2 shows the cost-effectiveness acceptability
curve based on mean ICERs from the analysis of uncer-
tainty. From a cost-effectiveness perspective, the prob-
ability that ICU admission should be preferred to
general ward care was 95% for all patients, 97% for med-
ical, 93% for acute surgical, and 84% for planned surgical
patients at a threshold of €22,000/QALY.
Figure 3 shows the disaggregated individual results.
Each line is made up of 30,712 points. Each point repre-
sents the ICER for an individual admission. The individ-
ualized ICERs are sorted from the lowest (left) to the
highest (right) ICER. One line represents the variability
across modelled individuals. The cloud of 1000 light grey
lines represents parameter uncertainty.
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The black line shows the median individualized results
from the probabilistic analysis. The median is the
equivalent to 50% probability of cost-effectiveness. There
was a 50% probability (median) that ICU admission was
cost-effective for 85% of the patients at a threshold of
€64,000/QALY (Fig. 3a). The remaining 15% median in-
dividualized ICERs were above €64,000/QALY, and con-
stituted 12% of medical admissions, 14% of admissions
Fig. 2 a Cost-effectiveness acceptability curve: all patients. The probability that ICU admission versus general ward care was cost-effective was
95% at a threshold of €22,000/QALY (threshold indicated by long dashed line). b Cost-effectiveness acceptability curve: by type of admission. The
probability that ICU admission versus general ward care was cost-effective by type of admission. Threshold of €22,000/QALY indicated by long
dashed line. ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year
Table 3 Mean cost-effectiveness of ICU admission versus hypothetical general ward care. Data from Norway*
Patient group ICU strategy Costs Incremental costs QALYs Incremental QALYs Incremental C/E Prob C/Ea Distr C/Eb
All (n = 30,712)
Reject 16,100 6.1 (11.6)
Admit 34,800 18,700 7.7 (14.4) 1.6 (2.8) 11,600 0.95 5000
Medical (n = 17122)
Reject 15,300 5.7 (10.9)
Admit 33,500 18,200 7.4 (13.8) 1.7 (2.9) 10,700 0.97 4600
Acute surgery (n = 9722)
Reject 16,200 6.5 (12.9)
Admit 36,900 20,700 8.2 (15.8) 1.7 (2.9) 12,300 0.93 5400
Planned surgery (n = 3868)
Reject 19,200 6.6 (11.5)
Admit 35,400 16,200 7.7 (13.4) 1.1 (1.9) 14,700 0.84 6500
* The numbers are average extra costs in Euro or health gains in quality-adjusted life years (QALYs) per patient. Costs and QALYs were discounted at 4% annually
(undiscounted QALYs in brackets)
aUsing a general cost-effectiveness threshold of €22,000/QALY
bResults after health gains were weighted according to the patient’s lifetime QALYs in case of general ward care (severity of disease)
C/E cost-effectiveness, Distr distribution-weighted, Prob probability
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after acute surgery, and 34% of admissions after planned
surgery (probability = 50%; Fig. 3b).
On average, ICU admission was more costly than gen-
eral ward care for all draws in the probabilistic analysis.
However, the lines left of zero on the x axis in Fig. 3a and
b illustrate that ICU admission was found to be cost-
saving in a small proportion of the individualized models.
Distribution-weighted economic evaluation
The ICER for the entire intensive care population was
€11,600/QALY; the impact of distribution weights ac-
cording to severity of disease reduced this mean ICER to
€5000/QALY. In the distributional evaluation, only 8%
of all patients had distribution-weighted ICERs above
€64,000/QALY due to higher weights to gains for more
severe conditions (probability = 50%; Fig. 3). Patients
with distribution-weighted ICERs above €64,000/QALY
represented 6% of medical admissions, 7% of admissions
after acute surgery, and 23% of admissions after planned
surgery. All of these patients could expect more than 68
lifetime QALYs if not admitted to the ICU.
The average severity of disease was 66.5 undiscounted
QALYs over a lifetime if not treated in the ICU, and the
mean undiscounted gain from admission was 2.8 QALYs.
Patients with the highest severity of disease (<50 lifetime
QALYs, mean = 42.6 undiscounted QALYs) gained the
most from admission, 13.8 undiscounted QALYs per pa-
tient on average, and these admissions were most cost-
effective. Patients with low severity of disease (65+ life-
time QALYs, mean = 70 undiscounted QALYs) gained
1.1 undiscounted QALYs per patient. The resulting life-
time total if admitted to the ICU was 68.3 QALYs (all
patients), 56.4 QALYs among patients with the highest
Fig. 3 a Individualized cost-effectiveness with and without distribution weights for severity of disease: the disaggregated individual results. Each
line is made up of 30,712 points. Each point represents the ICER for an individual admission. The individualized ICERs are sorted from the lowest (left)
to the highest (right) ICER. There was a 50% probability (median, black line) that ICU admission was cost-effective for 85% of the patients at a threshold
of €64,000/QALY (long dashed line). The figure illustrates that after assigning distribution weights according to severity of disease, i.e. higher weights to
the health gains of patients with fewer lifetime QALYs if rejected, ICU admission can be considered acceptable for more patients (thick grey line) for
any cost-effectiveness threshold compared to the standard analysis (black line). b Individualized cost-effectiveness in subgroups by type of admission.
The individualized incremental cost-effectiveness ratios were plotted as points forming a line. The individualized ICERs are sorted from the lowest (left)
to the highest (right) ICER. The thick black line is the median result for each individual from 1000 replications of the model. The long dashed line indi-
cates a general cost-effectiveness threshold of €64,000/QALY. ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year
Lindemark et al. Critical Care  (2017) 21:220 Page 9 of 13
severity of disease, and 71.1 among those with low sever-
ity of disease.
Scenario analyses
In the scenario analyses the same pattern emerged as in
the main analysis. The mean cost-effectiveness of ICU
admission versus ward care was €12,000/QALY (p =
95%), with 1.6 QALYs gained from ICU admission and
an incremental cost of €19,100 per patient, when assum-
ing a smaller difference between the first and later daily
costs. Medical admissions (€11,000/QALY, p = 98%) had
a more favourable ICER than admissions after acute sur-
gery (€13,000/QALY, p = 92%) and after planned surgery
(€14,600/QALY, p = 84%). When we included lifetime
health care cost, the mean cost-effectiveness of ICU ad-
mission versus ward care was €13,900/QALY (p = 91%),
with 1.6 QALYs gained from ICU admission and an in-
cremental cost of €22,200 per patient. Medical admis-
sions (€13,000/QALY, p = 95%) had a more favourable
ICER than admissions after acute surgery (€14,600/
QALY, p = 87%) and after planned surgery (€17,100/
QALY, p = 73%).
Discussion
The main finding of this modelling study is that the
average health gain per patient from ICU admission was
1.6 QALYs at an incremental cost of €18,700 compared
with treating the same patients in general wards. The
resulting mean ICER of ICU admission was €11,600/
QALY, and would be considered cost-effective over
common cost-effectiveness thresholds, including the
Norwegian setting at a threshold range of €22,000–
64,000/QALY. The probability of ICU admission being
cost-effective was 95% at a threshold of €22,000/QALY.
By contrast, the disaggregated results demonstrate a
much greater uncertainty given by the range in probabil-
ity of cost-effectiveness due to individual variability and
uncertainty around input parameters. There was a 50%
probability that ICU admission was cost-effective for
85% of the patients at a threshold of €64,000/QALY. At
this level of uncertainty, about one sixth of the individ-
ual patient admissions were estimated to be not cost-ef-
fective. Half of these, and consequently 92% of all
individual admissions, had an acceptable relationship be-
tween resource use and health gains in the distributional
analysis giving extra weight to health gains for those
with higher severity of disease (probability = 50%).
Our study contributes in three main areas. First, it is
the first study from a Nordic country that estimated the
difference in costs and QALYs between ICU admission
and ward care. Second, we account for the heterogeneity
and distribution of incremental costs and health gains in
a nationwide ICU population. We modelled individual
admissions using real data from NIR to describe
variability across admissions; the variation in the cost-
effectiveness across individuals is due to observed
differences in their profile of length of stay, short-term
risk of death and age, and effect size. Third, in the ex-
plorative distribution-weighted evaluation we adjusted
the ICER by severity of disease in terms of lifetime
QALYs. ICU admission was more cost-effective among
high-severity patients (lifetime QALYs <50). Our study is
among the first to incorporate a concern for severity of
disease into a standard cost-effectiveness model by giv-
ing higher weight to health gains for the critically ill with
fewer lifetime QALYs if not admitted [58, 62]. This ap-
proach is relevant to health care systems where priority
setting aims at the twin goals of maximizing healthy life
years for all and reducing inequalities in lifetime health
across individuals or patient groups [13].
The main conclusion of the standard CEA is similar to
other studies from Europe that sought to estimate the dif-
ference in costs and health outcomes between adult pa-
tients accepted and rejected to the ICU. The mean extra
costs of ICU versus non-ICU care per patient of €18,700
are higher than previous reports. Edbrooke et al. estimated
the extra hospital costs to be €4886 in 2005 (multicentre,
Europe) [9]. Ridley and Morris included extra hospital
costs plus discounted lifetime average health care costs of
extra survivors due to ICU support (£8902 in 2003, UK)
[10]. NIR lacks data about the long-term economic conse-
quences of critical illness. We therefore applied available
data from Scotland on hospital resource use in ICU survi-
vors up to 5 years after the initial admission [48]. ICU ad-
mission after planned surgery was less cost-effective than
after acute surgery and medical admissions. This can be
explained by a lower hospital mortality, lower SAPS II
and, therefore, lower expected health benefits (1.1 QALYs)
from ICU admission after planned surgery (Tables 2 and
3). Edbrooke et al. found that patients with low, medium,
and high predicted short-term risk of death have variable
effect from ICU admission, and concluded that ICU ad-
mission is more cost-effective with increasing severity as
measured by SAPS II [9]. One strength of our study is that
we varied the survival benefit according to SAPS II and es-
timated expected outcomes for individual admissions. The
distribution of individualized ICERs shows that behind the
average results for the population as a whole there are a
number of patients where ICU admission is predicted not
to be cost-effective. In the probabilistic analysis, 15% of
the patient profiles had a median cost to effect ratio of
more than €64,000/QALY. Currently, new health care
technologies such as cancer immunotherapies with an
ICER above this limit will not be reimbursed. Prioritising
interventions with such high ICERs may displace existing
health care activities that benefit patients more.
We note some limitations of our analysis. We rely on
crude estimates of the incremental costs of ICU versus
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ward care. We used the perspective of a decision maker
allocating resources within the hospital sector. We tried
to capture differences in direct costs of care for and
health benefits to the critically ill patients, but acknow-
ledge that there might be differences in the quality of
end-of-life care and in the burden of critical care and ill-
ness felt by patients and family members in the ICU
compared with the ward group [27]. The assumptions
regarding the hospital length of stay and costs for both
treatment options may under- or overestimate the differ-
ence in hospital costs. The length of the hospital stay
was unavailable in NIR. The probability that ICU admis-
sion was cost-effective at a threshold of €22,000/QALY
was high in the main analysis and scenario analyses, des-
pite the uncertainty around possible input parameters
and the broad ranges used. In scenario analysis, the extra
costs of ICU admission increased for medical admissions
(€18,400) and after acute surgery (€21,500) when we re-
duced the differences in daily costs throughout the ICU
or ward stay. The extra cost decreased in admissions
after planned surgery where ICU LOS was shorter com-
pared with the other types of admission (€15,700;
Table 2). A major challenge is the hypothetical nature of
the comparator. Since RCT data are not available, all
analysis must rely on counterfactual assumptions. The
assumptions about the effect of ICU admission were in-
formed by observational studies where patients refused
and accepted to the ICU are likely to differ in case mix.
We suspect effect estimates from these studies would
underestimate the mortality reduction among those who
benefit the most from ICU admission in a nationwide
ICU population. We sought to compensate for lack of
robust effect data by assuming that those with mid- to
high-range SAPS II benefit the most, as illustrated in
Fig. 1 [21]. Our study does not capture well how hospi-
tals deal with levels of care below high-level ICU (multi-
organ support), but above a regular ward. However, the
issue is partly taken into account through the uncer-
tainty range of model parameters (see Additional file 2
or effect and costs assumptions). The adjustment for ex-
cess long-term mortality and reduced HRQoL in hos-
pital survivors could be stratified by patient categories
(acute respiratory distress syndrome (ARDS), post-
sepsis, cancer, etc.). We did not have such information
to classify the NIR patients, and do not know if making
more detailed distinctions among patients would impact
on overall results or the distribution of individualized
ICERs.
The methodology using a large individual-level (ICU)
database to account for sub-group heterogeneity and in-
dividual variability of costs and expected outcomes is
relevant to any country considering cost-effectiveness in-
formation in priority setting to improve health as much
as possible. The cost-effectiveness results may at least be
generalizable to other Scandinavian countries as the case
mix of our ICU populations and ICU and health systems
organisation are similar [59]. The study provides useful
contextual information about the relationship between
extra costs and health gains associated with current ICU
care compared to other high-cost health care competing
for the same resources [60]. Introducing new high-cost
technologies with less favourable cost-effectiveness ratios
than ICUs may have opportunity costs in terms of
healthy life years forgone. The study does not directly
inform a priority-setting task of choosing between spe-
cific future policy options since it does not assess a new
intervention, such as scaling up ICU care by admitting
more or other types of patients from the at-risk popula-
tion before triage, or modernizing care of the critically ill
by introducing intermediate care units [3, 17].
Even if patient groups may be denied access to an
intervention because the mean group-level cost-
effectiveness ratio of the intervention is above an ac-
cepted threshold value, clinicians may identify individual
cases who are likely to benefit more and/or cost less
than the expected average [61]. In intensive care, our
findings suggest that we have the opposite case: overall
ICU admission versus ward care is predicted to be cost-
effective, but a number of patients are expected to have
ICU admissions that are not cost-effective. If we can
identify these types of individual ICU patients, should
we then deny them treatment on grounds of cost-
effectiveness? We believe drawing such a conclusion is
premature. Given the difficulty of ICU triage and the
uncertainty around selecting those who can benefit the
most from admission to a reasonable cost, we may have
to accept the great variability in individualized ICERs,
and leave judgement to clinicians and clinical guidelines,
as long as the average results can be considered cost-
effective. Clinicians must be cautious about the assump-
tions underlying the individualized cost-effectiveness
estimates and their use for a particular individual [11].
Conclusion
This micro-simulation modelling study predicts that
ICU admission versus general ward care of the same pa-
tients if not admitted to the ICU is likely to be cost-
effective (mean ICER €11,600/QALY, p = 0.95) at a
threshold of €22,000/QALY. The study provides a rough
sense of the relationship between the expected costs of,
and QALY gains from, ICU admission, and demonstrates
that behind overall mean cost-effectiveness results there
will be a great degree of variation and uncertainty of
ICERs among individual types of ICU patients. Accord-
ing to the individualized cost-effectiveness information,
about one in six ICU admissions are predicted to be not
cost-effective at a threshold of €64,000/QALY. Accord-
ing to the distribution-weighted analysis, almost half of
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these not cost-effective admissions can be regarded as
acceptable when weighted by severity of disease in terms
of expected lifetime health. The analysis informs a public
policy to expand ICU capacity to maintain today’s level
of ICU services in the face of increased need due to
changing demographics.
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